REMS Can’t Help Endo’s Aveed – Won’t Address Unpredictable Safety Events, FDA Advisors Say
Executive Summary
Without predictive factors to determine who is likely to get a severe post-injection reaction, FDA advisory committees say Endo’s proposed REMS for its long-acting testosterone is unlikely to allay safety concerns.
You may also be interested in...
US FDA Taps Pfizer Executive For CDER Deputy Director Slot
Patrizia Cavazzoni, Janet Woodcock's new #2, has a background similar to Richard Moscicki, CDER's previous deputy director for operations.
Endo Gets Surprise Aveed Approval, But REMS Could Be A Roadblock
After seven years of rejection, Endo finally gets FDA’s go-ahead on its long-acting testosterone treatment, but a strict REMS program and plenty of market competitors will make the drug’s launch difficult.
Testosterone Petition From Public Citizen Eyes Industry Bias In Risk Findings
Seeking immediate relabeling of the products, advocacy group notes a meta-analysis found different CV risk depending on who funded the studies analyzed.